Mylan, Abbott Bury Hatchet Over Depakote ER

Law360, New York (June 5, 2008, 12:00 AM EDT) -- Mylan Pharmaceuticals Inc. and Abbott Laboratories have reached a truce in their long-standing battle over Depakote, as Mylan won permission to sell a knockoff version of Abbott's best-selling extended-release epilepsy drug.

West-Virginia based Mylan, a subsidiary of multinational Mylan Inc., disclosed Thursday in a filing with the U.S. Securities & Exchange Commission that it will enjoy a 180-day exclusivity period to sell a 500 mg version of divalproex ER tablets upon launching, scheduled to take place no later than Jan. 1, 2009.

Under the deal, which...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.